Skip to main content

Table 1 Demographic and clinical characteristics of the study patients

From: Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study

  UC (n = 35) CD (n = 252)
Observational period, months, median (min, max) 27.6 (24, 60) 40.0 (24, 60)
Male, n (%) 19 (54.3) 188 (74.6)
Age, years, mean (SD) 43.1 (14.2) 31.9 (11.3)
BMI, mean (SD) 19.48 (2.47) 18.90 (2.98)
Extraintestinal manifestations within 2 years, n (%) 4 (11.4) 4 (1.6)
Duration of IBD, years, median (IQR)
Since appearance of IBD symptoms 3.0 (1.0, 6.0) 3.0 (1.0, 6.0)
Since diagnosis 1.0 (0.0, 4.0) 0.0 (0.0, 1.0)
IBD-related surgery since diagnosis, n (%)a 0 (0) 65 (26.6)
UC disease location at diagnosis, n (%)
Proctitis involvement limited to the rectum 2 (5.7)
Left-sided involvement limited to the proportion of the colon distal to the splenic flexure 7 (20.0)
Extensive involvement extends proximal to the splenic flexure, including pancolitis 21 (60.0)
Unknown 5 (14.3)
CD disease location at diagnosis, n (%)b
Ileal with upper GI disease (L1 + L4) 21 (8.3)
Ileal without upper GI disease (L1) 18 (7.1)
Colonic with upper GI disease (L2 + L4) 19 (7.5)
Colonic without upper GI disease (L2) 30 (11.9)
Ileocolonic with upper GI disease (L3 + L4) 32 (12.7)
Ileocolonic without upper GI disease (L3) 104 (41.3)
Unknown 28 (11.1)
Disease activity, n (%)
Normal 0 (0.0) 13 (5.2)
Mild 0 (0.0) 25 (9.9)
Moderate 4 (11.4) 34 (13.5)
Severe 22 (62.9) 24 (9.5)
Unknown 9 (25.7) 156 (61.9)
Biochemical activity, n (%)
Normal 5 (14.3) 52 (20.6)
Active 26 (74.3) 159 (63.1)
Unknown 4 (11.4) 41 (16.3)
Disease behavior, n (%)b
Non-stricturing, non-penetrating with perianal disease (B1p) 60 (23.8)
Non-stricturing, non-penetrating without perianal disease (B1) 49 (19.4)
Stricturing with perianal disease (B2p) 40 (15.9)
Stricturing without perianal disease (B2) 30 (11.9)
Penetrating with perianal disease (B3p) 17 (6.7)
Penetrating without perianal disease (B3) 23 (9.1)
Unknown 33 (13.1)
Prior non-biologic therapy, n (%)
Yes 27 (77.1) 101 (40.1)
No 7 (20.0) 147 (58.3)
Unknown 1 (2.9) 4 (1.6)
Prior non-biologic therapy, n (%)
Aminosalicylates 21 (77.8) 66 (65.3)
Antibiotics 9 (33.3) 20 (19.8)
Corticosteroids 16 (59.3) 47 (46.5)
Immunosuppressants 11 (40.7) 47 (46.5)
 Azathioprine 6 (22.2) 44 (43.6)
 Mercaptopurine 3 (11.1) 0 (0.0)
 Methotrexate 1 (3.7) 5 (5.0)
 Thalidomide 0 (0.0) 6 (5.9)
 Tacrolimus 1 (3.7) 1 (1.0)
 Cyclosporine A 0 (0.0) 1 (1.0)
Nutritional therapies 2 (7.4) 33 (32.7)
Other 15 (55.6) 46 (45.5)
Corticosteroid status
Intolerant 0 6 (2.4)
Dependent 13 (37.1) 23 (9.1)
Not dependent or intolerant 9 (25.7) 21 (8.3)
Unknown 13 (37.1) 202 (80.2)
Duration of non-biologic therapy discontinued before index date, months, mean (SD)c 1.2 (2.1) 1.1 (2.5)
Concomitant non-biologic therapy at index date, n (%) 24 (68.6) 108 (42.9)
Aminosalicylates 19 (54.3) 77 (30.6)
Corticosteroids 8 (22.9) 35 (13.9)
Immunosuppressants 5 (14.3) 22 (8.7)
  1. BMI body mass index, CD Crohn’s disease, GI gastrointestinal, IBD inflammatory bowel disease, IQR interquartile range, UC ulcerative colitis, SD standard deviation
  2. aIBD-related surgeries including total proctocolectomy, total and partial colectomy, ileocolonic bowel resection, small bowel resection, strictureplasty, perianal surgery, ileostomy reversal; bMontreal classification; cn = 31 for UC and n = 67 for CD